{"id":"W3167136803","doi":"10.1016/j.cgh.2021.06.011","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; University of California, San Francisco; Genentech; Ferring Pharmaceuticals; UCB; Biogen; National Institute of Diabetes and Digestive and Kidney Diseases; Seres Therapeutics; Hospira; Johns Hopkins University; Boehringer Ingelheim; Janssen Pharmaceuticals; CMC Microsystems; Gilead Sciences; AbbVie; Abbott Laboratories; Merck; Crohn's and Colitis Foundation of America; AstraZeneca; Pfizer","keywords":"Medicine; Ulcerative colitis; Internal medicine; Gastroenterology; Inflammatory bowel disease; Calprotectin; Adverse effect; Population; Tolerability; Immunology; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005730339,0.0002856147,0.0007069091,0.00004428685,0.0002107188,0.00002651696,0.0001448034,0.0003718809,0.00003927036],"category_scores_gemma":[0.0005937598,0.0002889841,0.0001738169,0.00003827678,0.0007566144,0.000008014425,0.0003020055,0.0002515001,0.000004720066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001012906,"about_ca_system_score_gemma":0.0001259672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003377484,"about_ca_topic_score_gemma":0.000473952,"domain_scores_codex":[0.9967113,0.000942627,0.00078012,0.0009581394,0.00006561905,0.0005422085],"domain_scores_gemma":[0.9986829,0.0002215424,0.0001980309,0.0004065277,0.0002026031,0.0002884102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01985924,0.00594924,0.9664233,0.00004326851,0.0005823378,0.0008068361,0.0001032856,0.000001896976,0.002390432,0.0002245447,0.0005749192,0.003040661],"study_design_scores_gemma":[0.02459292,0.01365488,0.9531044,0.00001595266,0.0003100187,0.0004189384,0.000331619,0.0002284845,0.0004666123,0.0001100267,0.006503135,0.0002630224],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950857,0.000214339,0.002719834,0.0006124991,0.0004268019,0.0006993714,0.000147368,0.00002169881,0.00007241199],"genre_scores_gemma":[0.9958501,0.0003236596,0.0003602773,0.002665569,0.0002819329,0.0000543834,0.000342525,0.00002880067,0.00009272949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01331895,"threshold_uncertainty_score":0.9999563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02881228585038049,"score_gpt":0.3652693861898719,"score_spread":0.3364571003394914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}